Ftse Mib
34.657,35
0,93%
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
NASDAQ
16.340,87
-0,03%
Bitcoin
61.250,89
0,74%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Neumora Therapeutics Inc (NMRA) Neumora Therapeutics Inc (NMRA) Notizie

Neumora Therapeutics Inc

NMRA
9,19
-0,58 (-5,94%)
11 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/5/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202413:15EDGAR2Form 8-K - Current report
07/5/202413:00GLOBENeumora Therapeutics Reports First Quarter 2024 Financial..
06/5/202413:00GLOBENeumora Therapeutics to Participate in Upcoming Conferences..
15/4/202412:30GLOBENeumora Therapeutics Announces Clinical Hold of Phase 1..
13/3/202412:00GLOBENeumora Therapeutics to Participate at Stifel 2024 Virtual..
07/3/202422:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/3/202413:08EDGAR2Form 8-K - Current report
07/3/202413:00GLOBENeumora Therapeutics Reports Fourth Quarter and Full Year..
16/2/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202413:00GLOBENeumora Therapeutics Appoints Kaya Pai Panandiker as Chief..
08/1/202414:32EDGAR2Form 8-K - Current report
02/1/202413:00GLOBENeumora Therapeutics to Present at 42nd Annual J.P. Morgan..
15/12/202323:06EDGAR2Form SC 13D/A - General statement of acquisition of..
12/12/202313:00GLOBENeumora Therapeutics Appoints Jason Duncan as Chief Legal..
28/11/202322:21EDGAR2Form 8-K - Current report
27/11/202313:00GLOBENeumora Therapeutics Announces NMRA-266 IND Clearance and..
01/11/202321:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202321:01EDGAR2Form 8-K - Current report
01/11/202312:00GLOBENeumora Therapeutics Reports Third Quarter 2023 Financial..
30/10/202312:00GLOBENeumora Therapeutics to Participate in Upcoming Conferences..
10/10/202313:00GLOBENeumora Therapeutics Announces Appointment of Robert Lenz,..
15/9/202302:49GLOBENeumora Therapeutics Announces Pricing of Initial Public..
Apertura: 9,85 Min: 9,02 Max: 9,97
Chiusura: 9,77

La tua Cronologia

NASDAQ
NMRA
Neumora Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network